Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Denali Therapeutics Inc. (DNLI)  
$20.73 1.39 (6.28%) as of 4:30 Fri 6/14


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 119,920,000
Market Cap: 2.49(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $14.96 - $32.49
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:

   

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Denali Therapeutics is a biopharmaceutical company that discovers and develops therapeutics to defeat neurodegenerative diseases. Co.'s clinical-stage programs are: leucine-rich repeat kinase 2 inhibitor program to address Parkinson's disease; enzyme transport vehicle :IDS program, its lead brain-penetrant enzyme replacement therapy, enabled by its enzyme transport vehicle, which is designed to restore iduronate 2-sulfatase, and reduce glycosaminoglycans, both peripherally and in the brain, in patients with mucopolysaccharidosis II; and eukaryotic initiation factor 2 B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 97,298 194,789 253,657 527,733
Total Sell Value $1,992,536 $3,809,170 $5,326,320 $13,514,934
Total People Sold 3 6 6 7
Total Sell Transactions 4 19 39 77
End Date 2024-03-17 2023-12-15 2023-06-16 2022-06-16

   
Records found: 416
  Page 17 of 17  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Watts Ryan J. President and CEO   •       •      –    2018-08-29 4 AS $18.05 $330,929 I/I (18,334) 2,784,304     -
   Schuth Alexander O. COO and Secretary   •       –      –    2018-06-22 4 OE $5.28 $31,247 D/D 5,918 5,918     -
   Fil Ltd See Remark 1   –       –      –    2017-12-12 4 A $0.00 $0 I/I 1,775,856 1,379     -
   Fil Ltd See Remark 1   –       –      –    2017-12-12 4 A $0.00 $0 D/D 1,497,951 1,914,833     -
   Crestline Management, Lp 10% Owner   –       –       •   2017-12-12 4 B $18.00 $4,950,000 I/I 275,000 19,462,499 1.5     -
   Crestline Management, Lp 10% Owner   –       –       •   2017-12-12 4 A $0.00 $0 I/I 19,986,798 1,111,799     -
   Fmr Corp See Remark 1   –       –      –    2017-12-12 4 A $0.00 $0 I/I 3,238,676 33,215     -
   Nelsen Robert Director   –       •       •   2017-12-12 4 A $0.00 $0 I/I 10,756,249 11,068,749     -
   Schenkein David P Director   –       •      –    2017-12-12 4 A $0.00 $0 I/I 249,998 19,774     -
   Flatley Jay T Director   –       •      –    2017-12-12 4 A $0.00 $0 I/I 250,000 250,000     -
   Tessier-Lavigne Marc Director   –       •      –    2017-12-12 4 A $0.00 $0 D/D 25,000 3,139,043     -
   Flagship Ventures Fund V General Partner Llc 10% Owner   –       –       •   2017-12-12 4 A $0.00 $0 D/D 8,606,249 8,918,749     -
   Watts Ryan J. President and CEO   •       •      –    2017-12-12 4 A $0.00 $0 D/D 12,500 12,500     -
   Bybee Clinton 10% Owner   –       –       •   2017-12-12 4 A $0.00 $0 D/D 10,756,249 11,068,749     -
   Sato Vicki L Director   –       •      –    2017-12-12 4 A $0.00 $0 D/D 62,500 137,500     -
   Krognes Steve E. CFO and Treasurer   •       –      –    2017-12-12 4 A $0.00 $0 I/I 500,000 1,000,000     -

  416 Records found
  Previous  10  11  12  13  14  15  16  17    
  Page 17 of 17
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed